How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mirtazapine-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Mirtazapine Tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mirtazapine Tablets (Mirtazapine Tablets) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracyclic antidepressant. Area: Psychiatry / Mental Health.

marketed Tetracyclic antidepressant Alpha-2 adrenergic receptor, 5-HT2 receptor, 5-HT3 receptor Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Mirtazapine Tablets (Mirtazapine Tablets) — National Institute of Mental Health, Dhaka. Mirtazapine blocks alpha-2 adrenergic receptors and serotonin 5-HT2 and 5-HT3 receptors, increasing noradrenergic and serotonergic neurotransmission in the central nervous system.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mirtazapine Tablets TARGET	Mirtazapine Tablets	National Institute of Mental Health, Dhaka	marketed	Tetracyclic antidepressant	Alpha-2 adrenergic receptor, 5-HT2 receptor, 5-HT3 receptor
Mirtazapine/SNRIs	Mirtazapine/SNRIs	Shanghai Mental Health Center	marketed	Tetracyclic antidepressant	Alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracyclic antidepressant class)

National Institute of Mental Health, Dhaka · 1 drug in this class
Shanghai Mental Health Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mirtazapine Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/mirtazapine-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing